Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bleomycin-induced fatal hyperpyrexia.

J J Carter, M L McLaughlin, M M Bern

    The American Journal of Medicine
    |March 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Bleomycin can cause acute hyperpyrexia, a dangerous fever reaction, especially after initial doses. This case highlights that pre-existing fever, like from lymphoma, may increase risk, suggesting fever reduction before bleomycin therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Black Hole Spectroscopy and Tests of General Relativity with GW250114.

    Physical review letters·2026
    Same author

    GW250114: Testing Hawking's Area Law and the Kerr Nature of Black Holes.

    Physical review letters·2025
    Same author

    Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007.

    Canadian journal of surgery. Journal canadien de chirurgie·2023
    Same author

    Sustainable dermatology: a service review at Warwick and quality improvement initiatives.

    Clinical and experimental dermatology·2021
    Same author

    Effects of anticoagulation on markers of activation of clotting following major orthopedic surgery.

    International journal of laboratory hematology·2015
    Same author

    Description of a new non-injectable connector to reduce the complications of arterial blood sampling.

    Anaesthesia·2014
    Same journal

    Marijuana Use and Acute Myocardial Infarction: Mechanistic Insights, Clinical Implications, and Emerging Challenges.

    The American journal of medicine·2026
    Same journal

    Cave Canem - Beware of the Dog.

    The American journal of medicine·2026
    Same journal

    Risk Factors for 30-day Hospital Readmission After Hospital-at-Home Treatment of Acute Pyelonephritis.

    The American journal of medicine·2026
    Same journal

    Mesenteric Panniculitis.

    The American journal of medicine·2026
    Same journal

    Hypercalcemia and hyperferritinemia in a patient with Graves' disease disease.

    The American journal of medicine·2026
    Same journal

    Looking Beyond the Frame: Storytelling, Identity, and the Illness Narrative.

    The American journal of medicine·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Toxicology

    Background:

    • Bleomycin is a standard chemotherapy agent for various cancers.
    • Common adverse effects include pulmonary, cutaneous, and bone marrow toxicity.
    • Acute hyperpyrexic reactions are a known, though less common, side effect, typically occurring after initial bleomycin administration.

    Observation:

    • A patient with lymphoma, previously treated with multiple bleomycin courses without fever, developed fulminant hyperpyrexia and died.
    • The patient had concurrent fever attributed to their lymphoma during the bleomycin treatment course.
    • This suggests a potential interaction where existing pyrexia lowers tolerance to drug-induced fever.

    Findings:

    • Fulminant hyperpyrexia and death occurred in a lymphoma patient during bleomycin therapy.

    Related Experiment Videos

  • Pre-existing lymphoma-associated fever may have critically reduced the threshold for severe bleomycin-induced hyperpyrexia.
  • This case underscores the potential for exacerbated drug toxicity in febrile patients.

    • Implications:

    • Consideration of a patient's baseline temperature and fever-inducing conditions is crucial before initiating bleomycin.
    • Reducing pre-existing fever prior to bleomycin administration may mitigate the risk of severe hyperpyrexic reactions.
    • Further investigation into the mechanisms of bleomycin-induced hyperpyrexia and its interaction with other pyretic conditions is warranted.